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Received May 15, 2012; accepted January 31, 2013AbstractBackground: Tripterygium is a Chinese herb with immunosuppressive effects and an established history of use in the treatment of rheumatoid
arthritis. Previous studies demonstrated that tripterygium glycosides (TPG) alleviated Freund’s complete adjuvant (FCA)-induced arthritis.
Simultaneously, it has also been observed to impact the adjuvant arthritis (AA) associated with lung injury. In this study, we have investigated
whether traditional Chinese medicine could attenuate lung injury induced by AA by observing the effects of TPG on the degree swelling,
arthritis index (AI), lung index (LI), pulmonary function, cytokines, and the expression of regulatory T cells (Treg) and Foxp3 in AA rats.
Methods: A total of 48 rats were separated into four groups: normal control (NC), model control (MC), methotrexate (MTX), and TPG groups
(12 in each). Except for the rats of NC group, those in the others groups were intracutaneously injected in the right hind limb with 0.1 ml of FCA.
The NC and MC groups were treated with physiological saline, and the MTX and TPG groups were treated with MTX and TPG, respectively.
Thirty days after administration, the changes in swelling degree, AI, LI, pulmonary function, Treg levels, the ultrastructure of the lung tissue, and
the expression of Foxp3 in the lung tissue were observed.
Results: Compared with NC group, the level of swelling degree, AI, LI, 1 second average expiratory flow (FEV1/FVC %), the alveolar
inflammation integration, tumor necrosis factor alpha (TNF-a), and endothelium-1 (ET-1) in the MC group had significantly increased
( p < 0.01). However, the level of forced vital capacity (FVC), 25% vital capacity of the peak expiratory flow (FEF25), 50% vital capacity of the
peak expiratory flow (FEF50), 75% vital capacity of the peak expiratory flow (FEF75), maximum mid-expiratory flow (MMF), peak expiratory
flow (PEF), interleukin-10 (IL-10), CD4þ CD25þ Treg, and Foxp3 had significantly decreased ( p < 0.01). LI, the alveolitis score, and ET-1 were
found to decrease with TPG treatment. However, the levels of FVC, FEF25, FEF50, FEF75, MMF, PEF, IL-10 in serum, and CD4
þ CD25þ Treg in
peripheral blood had increased. The expressions of Foxp3 protein and mRNA in the lung tissue had also increased in the TPG group. Compared
with the MTX group, the pulmonary function had enhanced, the structure of alveolar type II cells had improved, and the expression of the IL-10,
Treg, and Foxp3 had elevated. However, the TNF-a and ET-1 levels had reduced as compared to the MTX group.
Conclusion: The level of paw swelling and AI in the AA rats can be inhibited by TPG. The inflammatory response in lung tissue had also
decreased, although there was significant improvement in the pulmonary function. The mechanism that would explain this observation is
probably associated with the upregulation of the expression of IL-10, Treg, and Foxp3 and downregulation of the expression of TNF-a and ET-1.
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Rheumatoid arthritis (RA) is a chronic inflammatory, auto-
immune arthritis affecting mainly synovial joints, along with a
variety of other tissues and organs. The pathology findings inRA
include synovial cell edema and hyperplasia, abundant inflam-
matory cell infiltration, and fibroblast formation. This chal-
lenging disease may cause bone and joint destruction. The
process produces an inflammatory response of the synovium
secondary to the hyperplasia of synovial cells, excess synovial
fluid, and the development of pannus in the synovium. The pa-
thology of the disease process often leads to the destruction of
articular cartilage and ankylosis of the joints. RA can also in-
volves the lungs and lead to interstitial lung disease. The inter-
stitial lung disease occurs in about 28%of theRApatients, either
at the beginning or during their disease in china. The presence of
rheumatoid lung disease is associated with severe active disease
and increased mortality compared to the general population.
However, the etiology of rheumatoid lung disease at this time is
unknown. A prior study suggested that its pathogenesis may be
related to CD4þ CD25þ regulatory T cells (Treg) and Foxp3.1,2
Tripterygium glycosides (TPG) are also known as triptolide (TP,
Fig. 1). Tripterygium wilfordii is a traditional medicinal plant
and has been used in China for many years to treat inflammatory
joint diseases, including RA. In this study, we intended to detail
whether the administration of TPG is superior to methotrexate
(MTX) in improving the paw swelling degree, arthritis index
(AI), pulmonary function, and other previously noted factors in
adjuvant arthritis (AA) rats.
2. Methods2.1. Experimental animalsA total of 48 male Wistar rats, weighing from 200 g to
220 g, were purchased from the Experimental Animal Center
of Nanjing Medical University (Nanjing, China), certificate
No. SCXK(SU)2008-0004. The study protocol was approved
by the Ethics Committee of First Affiliated Hospital, Anhui
University of Chinese Medicine (Hefei, China). All animals
were housed under specific-pathogen-free (SPF) conditions,
and given free access to water and standard rat chow.2.2. DrugsMTX, in 2.5-mg tablet form, was produced by Shanghai
Traditional Chinese Medicine Co., Ltd., Xinyi PharmaceuticalFig. 1. Triptolide molecular structure.Factory, Shanghai, China (batch: 20090104). TPG, in 10-mg
tablet form, was produced by Shanghai Medical Hongqi
Pharmaceutical Factory, Shanghai, China (batch: 20091102).2.3. ReagentsFreund’s complete adjuvant (FCA) was obtained through
Sigma-Aldrich, St. Louis, MO, USA, (lot: 098k8729). Elisa kit
was purchased from R&D Systems, Minneapolis, MN, USA.
This also included interleukin-10 (IL-10, lot: 341225), tumor
necrosis factor alpha (TNF-a, lot: 341012), and Endothelin-1
(ET-1, lot: 340918). Regulatory T cells kit anti-mouse CD4-
FITC was purchased through eBioscience, USA (lot: 11-0040,
Clone: OX35), and anti-mouse CD25-PE was purchased from
BioLegend, San Diego, CA, USA (lot: 202105, Clone: OX-39).
The following were also used in this study: PCRMasterMix Kit
and M-MuLV Reverse Kit (Fermentas, Canada, lots: K0171,
K1622, respectively), Anti-mouse FOXP3monoclonal antibody
(Bioworld Technology, Louis Park, Minneapolis, USA, lot:
BS2163), and b-actin pAb (Bioworld Technology, Louis Park,
Minneapolis, USA, lot: AP0060).2.4. Model copy, grouping, and administrationsA total of 48 male Wistar rats were randomly divided into
four groups: normal control (NC), model control (MC), MTX,
and TPG groups, with 12 rats in each group. Except for the
rats of the NC group, the others were intracutaneously injected
with 0.1 mL of FCA in the right hind limb. From 19 days after
infection, the NC and MC groups were treated with physio-
logical saline (1 mL/100 g per day);. the MTX and TPG
groups were treated with MTX (1 mL/100 g per week) and
TPG (1 mL/100 g per day), respectively for 30 days.2.5. Determination of the experimental index
2.5.1. Paw swelling and AI
The paw volume was measured in the right hind limb of
rats, and the swelling degree was calculated.3 Twelve days
after inflammation, the joints were observed and recorded, and
thereafter once in every 3 days. Calculation of AI,4 score from
0 to 5 according to the swelling and involved joints was made
using the following scale: 0 point, no swelling; 1 point,
swelling from little toe joint; 2 points, swelling from toe joints
and foot; 3 points, swelling from ankle and below; and 4
points, swelling from all of ankle.
2.5.2. Paw swelling degree
E (%) ¼ (Vt  Vn)/Vn  100% (Vn and Vt represent the
volume prior to and after modeling, respectively).
2.5.3. Lung index (LI)
LI ¼ Lung wet weight (mg)/body weight (g)  100%.
2.5.4. Morphology of lung tissues
Thirty days after infection, all the rats were killed. The lung
tissues were remove, and then fixed in 4% paraformaldehyde
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embedding. The sliced lung tissues were stained with
hematoxylin-eosin (HE). The extent of alveolitis integration
was determined using Szapiel’s method5: without alveolitis
(-); mild alveolitis (þ): lesions was confined to below 20% of
the total lung tissue; moderate alveolitis (þþ): lesions reach
about 4e50% of the total lung tissue; and severe alveolitis
(þþþ): lesions were greater than 50% of the total lung tissue.
These results scored 0, 1, 2, and 3, respectively.
2.5.5. Electron microscopy of the ultrastructure of lung
tissues
Lung tissue was washed in phosphate buffer solution (PBS)
and then cut into the samples sized 1 mm  1 mm  1 mm for
each piece. It was fixed in glutaraldehyde (100 mL/L), imme-
diately followed by 1% osmic acid. Samples then underwent
alcohol dehydration and were embedded into an Epon812 resin
using standard procedures. Ultrathin sections (50 nm) were
stained with uranyl acetate and lead citrate. All specimens were
observed under the electronmicroscope (magnification: 8000).
2.5.6. Pulmonary function
Pulmonary function tests included: forced vital capacity
(FVC), 1 second average expiratory flow (FEV1/FVC), 25%vital
capacity of the peak expiratory flow (FEF25), 50% vital capacity
of the peak expiratory flow (FEF50), 75% vital capacity of the
peak expiratory flow (FEF75), maximum mid-expiratory flow
(MMF), and peak expiratory flow (PEF). The pulmonary func-
tion was tested by the animal lung function analysis system
(Beijing Bei Lanbo Technology Co., China; model: AniRes
2003). The procedures for pulmonary function testswere done as
follows6: the rats were anesthetized with chloral hydrate (10%,
0.35 mL/100 g) through intraperitoneal injection; they under-
went tracheotomy endotracheal intubation; the head was kept
lower; and the ventilator tube was connected to the mechanical
ventilation device to test the pulmonary function. The computer
measured each test automatically, quickly, and accurately.
2.5.7. Detection of CD4þ CD25þ Treg by flow cytometry
Fresh blood samples were collected from the rats, and
whole blood samples were taken into K3-EDTA-containing
tubes. Then, anti-mouse CD4-FITC (0.25 mg) and anti-mouse
CD25-PE (1.0 mg) were added to each tube of blood (106 cells
per tube) successively. The tubes were kept in dark for about
20e30 minutes at room temperature (20e25C). We then
added 1-mL red blood cell (RBC) lysate to the tube and
incubated it for 15e25 minutes again in the dark. Thereafter,
the tube contents were washed with PBA twice and centri-
fuged, wherein the supernatant was discarded. The expression
of CD4þ CD25þ Treg was measured by flow cytometry
(Beckman Coulter, Inc., USA, model: EPICS Altra).7
2.5.8. RTePCR
Total ribonucleic acid (RNA) was extracted by TRIzol
(TAKARA BIO, Otsu, Shiga, Japan) from 5  105 cells or
100-mg lung tissues and quantified using a spectrophotometer
(Eppendorf, Hamburg, Germany). Three micrograms of totalRNA was reverse transcribed into cDNA using Murine
Moloney Leukemia Virus Reverse Transcriptase (M-MLV RT;
Promega, Madison, WI, USA). PCR was carried out according
to the manufacturer’s instructions.
The following sequence specific primers were used for PCR
amplification. (1) The housekeeping gene GAPDH (GenBank
accession: NM-017008): sense: 50-TCC ACC ACC CTG TTG
CTG TAG-30, antisense: 50-CCA CAG TCC ATG CCA TCA
CT-3, and amplified fragment 258 bp. (2) The Foxp3 gene
(GenBank accession: NM-001108250): sense: 50-GCA AAC
GGA GTC TGC AAG TG-30, and antisense: 50-GCA GGA
GCT CTT GTC CAC TGA-30, and amplified fragment 450 bp.
The targeted DNA was amplified using PCR amplification
(Biometra Inc., Jena, Germany, model: T-Gradient Thermo-
block), and confirmed by electrophoresis (Amersham Bio-
sciences, Piscataway, USA, model: EPS-301) and sequencing.
PCR products were analyzed using gel image analysis system
(Bio-RAD Inc., Hercules, USA, model: Gel Doc XR) after
scanning the ethidium bromide-stained 1.5% agarose gel.
2.5.9. Western blotting
The protein concentration was determined using the Bradford
dye-binding assay with bovine serum albumin as the standard.
Cells were lysed in gel-loading buffer containing 50 mM Tris-
HCl (pH 6.8), 100 mM dithiothreitol (DTT), 2% sodium
dodecyl sulfate (SDS), 0.1% bromophenol blue, and 10% glyc-
erol. Fifty micrograms of total protein was resolved by SDS
polyacrylamide gel electrophoresis (PAGE) and electrically
blotted onto a nitrocellulose membrane (NC, millipore, Boston,
MA, USA, lot:HATF00010). The filters were blocked with
phosphate buffered saline (PBS) containing 15% nonfat milks.
Detection of Foxp3 or beta-Actin was carried out by
western blot analysis using the mouse anti-Foxp3 monoclonal
antibody (1:500, Bioworld Technology) or the rabbit anti-beta-
Actin polyclonal antibody (1:5000, Bioworld Technology) as
the primary antibody, and goat anti-mouse or goat anti-rabbit
IgG-conjugated horseradish peroxidase (Bioworld Technol-
ogy, Louis Park, Minneapolis, USA) as the secondary anti-
body. The bands were visualized by using the enhanced
chemiluminescence system (Pierce, Rockford, IL, USA).
2.5.10. Enzyme-linked immunosorbent assay (ELISA)
The levels of TNF-a, IL-10, and ET-1 in the supernatant of
different groups were measured using commercially available
ELISA kits (R&D System) according to the test protocols.
Values were expressed as pg/mL. The ELISA standard curve
was prepared using a serial dilution of TNF-a (IL-10 and ET-1)
standard protein concentrations. Absorbance was measured at
450 nm using an absorbance microplate reader (BioTek, Ver-
mont, USA,model: ELx800). The levels of recombinant TNF-a
(IL-10 and ET-1) in the supernatant of the cell culture were
calculated from the OD450 values according to the ELISA curve
within commercial TNF-a (IL-10 and ET-1) standards.
2.5.11. Immunohistochemistry
Lung tissues were obtained during operation, snap frozen
in liquid nitrogen, and stored at 80C. All slides were
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In brief, the tissues were dewaxed and rehydrated followed by
antigen retrieval through microwaving in 2 mM EDTA (pH
9.0) for Foxp3 antigen. Sections were blocked with 5% bovine
serum albumin (diluted in PBS) for 30 minutes and then
incubated with each primary antibody in a moist chamber at
4C overnight. Parallel sections from the same tissue block
were used for the staining of all the molecular variables. After
washing in PBS, the horseradish peroxidase (HRP) polymer-
linked secondary antibody was added for 60 minutes at
room temperature. The sections were then visualized with
diaminobenzidine (DAB) and counterstained with hematoxy-
lin. Sections for negative control were prepared using rabbit
IgG1 or mouse IgG1 instead of the primary antibody under the
same experimental conditions. 
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Fig. 2. (A) Influence of TPG on paw swelling degree in AA Rats. The extent of
paw swelling degree at different time points is shown for different groups. The
time points are as follows: prior to FCA injection, Day 19 after FCA injection,
and Day 30 after administration. The data are expressed as mean (n ¼ 12 for
each group). (B) Influence of TPG on AI in AA Rats. The expression of
arthritis index at different time points is shown. The time points are as follows:
Day 12 after FCA injection, Day 19 after FCA injection, and Day 30 after
administration. The data are expressed as mean (n ¼ 12 for each group).
AA ¼ adjuvant arthritis; AI ¼ arthritis index; FCA ¼ Freund’s completeContinuous variables were expressed as mean  standard
deviation (SD). All samples were tested to ascertain if they
followed a normal distribution. Data comparison among groups
was carried out using analysis of variance (ANOVA). Com-
parison between the groups was carried out using the inde-
pendent samples t test. SPSS version 13.0 software
(International Business Machines Corporation, Armonk, New
York City, USA) was used for data analyses. A p value <0.05
was considered significant.
3. Results
adjuvant; MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal control;
TPG ¼ tripterygium glycosides.3.1. Effects of TPG on paw swelling degree and AIAfter the FCA injection, paw swelling developed 12 hours
later, and there was no significant difference among three
groups (MC, MTX, and TPG groups). For the NC group,
however, there was no apparent paw swelling. When we
treated those rats with MTX or TPG, the level of paw swelling
and AI was significantly reduced when compared with the
untreated MC group (Fig. 2A and B).3.2. Effects of TPG on pulmonary function and lung
tissues in AA ratsForty-nine days after the FCA injection, the pulmonary
function was found to change significantly. It showed that the
parameters of the pulmonary function (FVC, FEV1/FVC,
FEF25, FEF50) were significantly reduced in the MC group.
However, when treated with MTX or TPG after 30 days, we
found that the values of FVC, FEV1/FVC, FEF25, FEF50,
FEF75, MMF, and PEF in the TPG and MTX groups were
higher than those in the MC group. When compared with the
MTX group, FVC, FEF25, FEF50, FEF75, MMF, and PEF were
increased in the TPG group. Meanwhile, the morphology of
lung tissues were improved, and these characteristics showed
that the levels of lung coefficient and alveolitis integration had
reduced ( p < 0.05 or p < 0.001; Table 1).3.3. Effects of TPG on type II cells of lung tissue in AA
ratsNC group: The structure of alveolar type II cells was intact,
there was no swelling in the mitochondria, and few lamellar
bodies were emptied (Fig. 3A). MC group: Alveolar type II
cells showed proliferation and swelling, the membrane is not
complete, there was swelling in the mitochondria, the lamellar
body was reduced and evacuated, and the mononuclear
macrophage was infiltrated and accumulated (Fig. 3B). MTX
group: The structure of alveolar type II cells was intact mostly,
there was no swelling in the mitochondria, and some lamellar
bodies were emptied, indicating macrophages granulocyte acid
(Fig. 3C). TPG group: There were obvious neutrophils,
monocytes, macrophages within and around the structure of
alveolar type II cells. The most mitochondria were intact, while
few lamellar bodies were emptied in the type II cells (Fig. 3D).3.4. Effects of TPG on TNF-a, IL-10, and ET-1 in AA
ratsForty-nine days after the FCA injection, compared to the
NC group, the concentrations of TNF-a, ET-1 in serum, and
ET-1 in the lung tissue were significantly increased; IL-10 in
serum had decreased noticeably in the MC group ( p < 0.001).
Table 1
Comparisons of pulmonary function, LI, and alveolitis in each group (n ¼ 12, mean  SD).
Index Groups
NC MC MTX TPG
Pulmonary function
FVC (mL) 6.09  2.01 5.07  0.27* 5.25  0.25* 5.89  0.30***,*****
FEV1/FVC (mL) 57.7  5.79 68.6  6.38* 64.5  7.61** 60.2  7.28***
FEF25 (mL/s) 45.2  6.21 30.7  2.81* 36.8  3.67*,*** 42.2  4.71***,****
FEF50 (mL/s) 39.4  6.84 27.0  6.07* 30.3  4.94* 40.2  4.36***,*****
FEF75 (mL/s) 37.7  5.87 37.7  5.87 24.1  5.80* 34.4  10.5***,****
MMF (mL/s) 39.2  5.72 39.2  5.72 31.7  4.36* 37.1  4.62***,****
PEF (mL/s) 39.1  4.87 39.1  4.87 33.1  3.12* 37.8  4.33***,****
Lung index 2.61  0.08 0.36  0.36* 2.83  0.11*,*** 2.74  0.12*,***,****
Alveolitis points (point) 0.37  0.74 2.75  0.70* 1.87  0.35*,*** 1.62  0.51*,***,****
* Compared with the NC group, p < 0.001.
** Compared with the NC group, p < 0.05.
*** Compared with the MC group, p < 0.001.
**** Compared with the MTX group, p < 0.05.
***** Compared with the MTX group, p < 0.001.
FEF25 ¼ 25% vital capacity of the peak expiratory flow; FEF50 ¼ 50% vital capacity of the peak expiratory flow; FEF75 ¼ 75% vital capacity of the peak
expiratory flow; FEV1/FVC ¼ 1 second average expiratory flow; FVC ¼ forced vital capacity; LI ¼ lung index; MC ¼ model control; MMF ¼ maximum mid-
expiratory flow; MTX ¼ methotrexate; NC ¼ normal control; PEF ¼ peak expiratory flow; SD ¼ standard deviation; TPG ¼ tripterygium glycosides.
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between the treated and untreated groups. The concentrations
of TNF-a and ET-1 in the TPG group were significantly lower
than those in the MC group, and the concentrations of IL-10
were significantly higher than those in the MC group
( p < 0.001). The differences in concentrations of TNF-a and
ET-1 between the TPG and MTX groups were statistically
significant. Compared to the MTX group, the levels of TNF-a
(serum) and ET-1 (lung tissue) had significantly reduced in the
TPG group ( p < 0.001; Table 2).3.5. Effects of TPG on Treg in peripheral blood and
Foxp3 expression in lung tissueIn order to further analyze the reasons of pulmonary
function injury and the effect of TPG on the treatment ofFig. 3. Ultrastructure changes in type II cells of the lung tissue in each group
(magnification: 8000) of (A) NC, (B) MC, (C) MTX, and (D) TPG groups are
significantly better than the other groups. MC ¼ model control; MTX ¼ methotrepulmonary function in AA rats, we detected Treg expression
by flow cytometry (FCM) in peripheral blood (Fig. 4AeE);
immunohistochemistry (Fig. 5AeD), reverse transcription
polymerase chain reaction (RT-PCR) (Fig. 6AeC), and west-
ern blot (Fig. 7AeC), which were used to detect the expres-
sion of Foxp3 in the lung tissue. Flow cytometry results
showed that the expression of CD4þ CD25þ Treg had
decreased significantly in the MC group (5.78  0.85%) and
increased in the TPG group (8.64  1.88%). Immunohisto-
chemistry results showed that the expression of Foxp3 in the
lung tissue was concentrated in the nucleus and cytoplasm.
There was low expression in the MC group, whereas high
expression in the TPG group. RT-PCR and western blot results
showed that the expressions of Foxp3 mRNA and protein had
decreased significantly in the MC group. Again, the TPG
group has higher expression than that in the MC group. TPG. Representative lead axis staining patterns at Day 30 after administration
shown. The improved type II cells of the lung tissue of the TPG group were
xate; NC ¼ normal control; TPG ¼ tripterygium glycosides.
Table 2
Comparisons of cytokines in each group (mean  SD).
Index Case Groups
NC MC MTX TPG
Cytokine in serum
TNF-a (pg/mL) 10 32.1  7.40 80.5  10.7* 59.8  20.3*,*** 53.2  19.7*,****
IL-10 (pg/mL) 10 106.6  14.7 51.5  20.1* 74.2  23.6*,*** 90.2  21.8****,*****
ET-1 (pg/mL) 10 19.0  8.11 48.3  16.8* 32.2  10.7*,*** 30.8  12.6**,***
Cytokine in lung tissue
ET-1 (pg/mL) 10 8.03  5.76 27.2  15.7** 20.2  11.9** 11.7  9.33***,******
* Compared with the NC group, p < 0.001.
** Compared with the NC group, p < 0.05.
*** Compared with the MC group, p < 0.05.
**** Compared with the MC group, p < 0.001.
***** Compared with the MTX group, p < 0.05.
****** Compared with the MTX group, p < 0.001.
ET ¼ endothelin; IL ¼ interleukin; MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal control; SD ¼ standard deviation; TNF ¼ tumor necrosis factor;
TPG ¼ tripterygium glycosides.
Fig. 4. The changes in CD4þ CD25þ regulatory T cells of peripheral blood in (A) MC, (B) NC, (C) TPG, and (D) MTX groups. The antimouse CD4 antibodies are
labeled by FITC fluorescence. The absorption and emission peaks are 492 nm and 520 nm, respectively. The antimouse CD25 antibodies are labeled by PE
fluorescence. The absorption and emission peaks are 488 nm and 525 nm, respectively. (E) Comparisons of CD4þ CD25þ regulatory T cells in each group. The
data are expressed as mean  SD (n ¼ 12 for each group). * Compared with the NC group, p < 0.001. ** Compared with the NC group, p < 0.05. *** Compared
with the MC group, p < 0.05. **** Compared with the MC group, p < 0.001. ***** Compared with the MTX group, p < 0.05. FITC ¼ fluorescein isothiocyanate;
MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal control; PE ¼ phycoerythrin; TPG ¼ tripterygium glycosides.
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Fig. 5. Foxp3 expression in lung tissue in (A) NC, (B) MC, (C) MTX, and (D) TPG groups. SP immunohistochemistry staining patterns at 30 days after
administration (magnification: 200). MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal control; TPG ¼ tripterygium glycosides.
721L. Wan et al. / Journal of the Chinese Medical Association 76 (2013) 715e723could improve the level of CD4þ CD25þ Treg and Foxp3,
when compared with the control drugs.
4. Discussion
Acute lung injury is a pulmonary characteristics of un-
controlled systemic inflammatory response syndrome (SIRS),***
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Fig. 6. Comparisons of Foxp3 mRNA expression in each group. The detection
of fork head protein p3 (Foxp3) mRNA in lung tissue by a semiquantitative
reverse transcription polymerase chain reaction (SQ-RT-PCR) assay. (A)
GAPDH (an inner control) and (B) Foxp3 (objective gene) are shown. Lanes 1,
2, 3, and 4 represent the MC, NC, MTX, and TPG groups, respectively. M
represents marker, and the amplification length unit is bp. (C) The level of the
integrated optical density of Foxp3 in the lung tissue. The data are expressed
as mean  SD (n ¼ 10 for each group). * Compared with the NC group,
p < 0.001. ** Compared with the NC group, p < 0.05. *** Compared with
MC group, p < 0.05. **** Compared with MTX group, p < 0.05.
MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal control;
TPG ¼ tripterygium glycosides.in which the activation of numerous inflammatory effector
cells, such as polymorph nuclear leukocytes and macrophages,
triggers the excessive release of inflammatory mediators and
cytokines. The mortality is still high in cases with severe acute
lung injury.
After inducing AA in the rats, the expressions of paw
swelling, AI, LI, FEV1/FVC%, alveolitis points, TNF-a, and
ET-1 were found to increase significantly ( p < 0.001),
whereas the levels of FVC, FEF25, FEF50, FEF75, MMF, PEF,
IL-10, CD4þ Treg, CD25þ Treg, CD4þ CD25þ Treg, and***
,
****
**
*
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
Group 
NC MC MTX TPG
In
te
gr
at
e
d 
O
pt
ic
al
 D
en
si
ty
A B
C
Fig. 7. Comparisons of Foxp3 protein expression in each group. The detection
of fork head protein p3 (Foxp3) protein in lung tissue by WB assay. (A) b-actin
(an inner control) and (B) Foxp3 protein (objective protein) are shown.
Lanes 1, 2, 3, and 4 represent the TPG, MTX, MC, and NC groups, respec-
tively. (C) The level of the integrated optical density of Foxp3 protein in
the lung tissue. The data are expressed as mean  SD (n ¼ 10 for each group).
* Compared with the NC group, p < 0.001. ** Compared with the NC group,
p < 0.05. *** Compared with MC group, p < 0.05. **** Compared with MTX
group, p < 0.05. MC ¼ model control; MTX ¼ methotrexate; NC ¼ normal
control; SD ¼ standard deviation; TPG ¼ tripterygium glycosides;
WB ¼ western blot.
722 L. Wan et al. / Journal of the Chinese Medical Association 76 (2013) 715e723Foxp3 in the lung tissue were found to decrease significantly
( p < 0.001). Our studies identified inflammatory reaction was
not only involved in the joint but also in the lung after FCA
injection. Pulmonary function change was indicated by the
observation of pulmonary ventilation function disorders,
particularly restrictive ventilatory disorder, which was
accompanied by a small airway obstruction. It should be
noticed that an imbalance between proinflammatory and anti-
inflammatory cytokine existed, suggesting that the inflamma-
tion occurred in both joints and lungs. The abnormal expres-
sion of regulated T cells and Foxp3 showed that Treg was
probably involved in RA pathogenesis of lung injury.8,9 It was
shown that Treg reduced pulmonary function parameters,
particularly for rats that did not receive any treatment. By
contrast, MTX and TPG could improve the pulmonary
function.
TP has been widely used in China to treat a broad spectrum
of autoimmune and inflammatory diseases, including RA. The
direct anti-inflammatory effects of TP were observed in the
croton oil-induced ear swelling, carrageenan-induced paw
edema, and air pouch model of carrageenan-stimulated acute
inflammation in animals. Significantly lower volumes of the
air pouch exudate, lower white blood cell counts with lower
percentages of neutrophils, and lower concentrations of in-
flammatory mediators, including TNF-a, were found in the
animals treated orally with the TP extract. Modern pharma-
cological studies show that TP exhibits anti-inflammatory and/
or immunomodulatory properties in experimental animals.
Pharmacological and clinical experiments also show that the
major effective component of TP is alkaloids, euonymus.
Alkaloids and euonymus can reduce capillary permeability,
inhibit exudation of inflammatory cytokines or chemokines,
inhibit or/and regulate the release of inflammatory mediators.
These effects can reduce the lung tissue damage.10 The
immunomodulatory effect of tripterygium ranged widely from
the humoral immunity to cellular immunity. TP (monomer)
has an inhibitory effect on inflammatory joint edema induced
by carrageenan, croton oil, and FCA. A study also showed that
TP could improve the recovery of alveolitis and fibrosis. TP
can reduce the area of alveolitis and pulmonary fibrosis, and
increase alveolar space.
In our results, compared with the AA rats, FVC, FEF25,
FEF50, FEF75, MMF, PEF, IL-10, and the levels of CD4
þ
CD25þ Treg and Foxp3 had significantly increased in the TP-
treated group, whereas paw swelling, AI, LI, FEV1/FVC%,
TNF-a, and ET-1 decreased, indicating that AA rats the rats,
arthritis induced by adjuvant, have swollen joints and
damaged lung tissue. The results manifested that the pulmo-
nary function decreases and there were disorders in the
immunological parameters. It should be noted that an imbal-
ance between proinflammatory and anti-inflammatory cyto-
kine existed, suggesting that the inflammation occurred in
both joints and lungs. We also found the treatment effect of
tripterygium was more noticeable than that of MTX.9,10 The
levels of CD4þ CD25þ Treg in peripheral blood of the AA
rats had clearly decreased. It may be correlated to the
breakdown of the autoimmune balance and the developmentof RA-induced lung injury, for a low-level of CD4þ CD25þ
Treg cannot sufficiently convert CD4þ CD25 T cells into
regulatory cells through immune induction after the inter-
vention of tripterygium, CD4þ CD25þ Treg was upregulated.
We proposed that as a consequence, the CD4þ CD25 T cells
can be converted into Treg to secrete IL-10 in the peripheral
blood of AA rats, thus promoting the expression of Foxp3 in
the lung tissue, then increasing the expression of anti-
inflammatory cytokine and decreasing the expression of
proinflammatory cytokines. Finally, the immunosuppression
of CD4þ CD25þ Treg is exemplified exclusively, as our data
implied. Our results showed that tripterygium can apparently
improve the pulmonary function in AA rats, and the mecha-
nism may be through the inhibition of the expression of TNF-
a, ET-1, upregulation of the level of CD4þ CD25þ Treg, and
promotion of the expression of IL-10 and Foxp3.11e15 In
conclusion, it is suggested that tripterygium can upregulate
CD4þ CD25þ Treg and Foxp3 expression, and this may
explain why tripterygium is effective in the treatment of RA.16
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